Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells

Liu,Tiancheng; Wu,Lisa  Y.; Fulton,Melody  D.; Johnson,Jacqueline  M.; Berkman,Clifford  E.

doi:10.3892/ijo.2012.1649

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells

Authors:
- Tiancheng Liu
- Lisa Y. Wu
- Melody D. Fulton
- Jacqueline M. Johnson
- Clifford E. Berkman
View Affiliations

Affiliations: Department of Chemistry, Washington State University, Pullman, WA 99164, USA
Published online on: October 4, 2012 https://doi.org/10.3892/ijo.2012.1649
Pages: 2087-2092

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Emergence of androgen-independent cancer cells during androgen deprivation therapy presents a significant challenge to successful treatment outcomes in prostate cancer. Elucidating the role of androgen deprivation in the transition from an androgen-dependent to an androgen-independent state may enable the development of more effective therapeutic strategies against prostate cancer. Herein, we describe an in vitro model for assessing the effects of continuous androgen-deprivation on prostate cancer cells (LNCaP) with respect to the expression of two prostate-specific markers: the androgen receptor (AR) and prostate-specific membrane antigen (PSMA). Compared with androgen-containing normal growth medium, androgen-deprived medium apparently induced the concomitant downregulation of AR and PSMA over time. Decreased protein levels were confirmed by fluorescence imaging, western blotting and enzymatic activity studies. In contrast to the current understanding of AR and PSMA in prostate cancer progression, our data demonstrated that androgen-deprivation induced a decrease in AR and PSMA levels in androgen-sensitive LNCaP cells, which may be associated with the development of more aggressive disease-state following androgen deprivation therapy.

View Figures

View References

1.	H GustavssonK WelenJE DamberTransition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesisProstate62364373200510.1002/pros.2014515389782
2.	Y NiuS AltuwaijriKP LaiAndrogen receptor is a tumor suppressor and proliferator in prostate cancerProc Natl Acad Sci USA1051218212187200810.1073/pnas.080470010518723679
3.	JN DavisKJ WojnoS DaignaultElevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancerCancer Res661189711906200610.1158/0008-5472.CAN-06-249717178887
4.	SO LeeSS DuttN NadimintyE PinderH LiaoAC GaoDevelopment of an androgen-deprivation induced and androgen suppressed human prostate cancer cell lineProstate6712931300200710.1002/pros.2062117626246
5.	P SaraonK JarviEP DiamandisMolecular alterations during progression of prostate cancer to androgen independenceClin Chem5713661375201110.1373/clinchem.2011.16597721956922
6.	HL DevlinM MudryjProgression of prostate cancer: multiple pathways to androgen independenceCancer Lett274177186200910.1016/j.canlet.2008.06.00718657355
7.	PA WatsonYF ChenMD BalbasConstitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptorProc Natl Acad Sci USA1071675916765201010.1073/pnas.1012443107
8.	TC YuanS VeeramaniFF LinAndrogen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cellsEndocr Relat Cancer13151167200610.1677/erc.1.01043
9.	K ZhangDJ WaxmanPC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesisMol Cancer9319201010.1186/1476-4598-9-31921190562
10.	KM BaeZ SuC FryeExpression of pluripotent stem cell reprogramming factors by prostate tumor initiating cellsJ Urol18320452053201010.1016/j.juro.2009.12.09220303530
11.	AK RajasekaranG AnilkumarJJ ChristiansenIs prostate-specific membrane antigen a multifunctional protein?Am J Physiol Cell Physiol288C975C981200510.1152/ajpcell.00506.200415840561
12.	SJ LeeK LeeX YangNFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigenJ Mol Biol330749760200310.1016/S0022-2836(03)00640-512850144
13.	A GhoshWD HestonTumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancerJ Cell Biochem91528539200410.1002/jcb.10661
14.	RS IsraeliCT PowellJG CorrWR FairWD HestonExpression of the prostate-specific membrane antigenCancer Res541807181119947511053
15.	T LiuLY WuMR HopkinsJK ChoiCE BerkmanA targeted low molecular weight near-infrared fluorescent probe for prostate cancerBioorg Med Chem Lett2071247126201010.1016/j.bmcl.2010.09.05720947349
16.	JY MatrouleCM CarthyDJ GranvilleO JoloisDW HuntJ PietteMechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitizationOncogene2040704084200110.1038/sj.onc.120454611494135
17.	T LiuLY WuCE BerkmanProstate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruptionCancer Lett296106112201010.1016/j.canlet.2010.04.00320452720
18.	T LiuY ToriyabeCE BerkmanPurification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatographyProtein Expr Purif49251255200610.1016/j.pep.2006.05.008
19.	T LiuLY WuM KazakCE BerkmanCell-surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigenProstate68955964200810.1002/pros.2075318361407
20.	LY WuMO AndersonY ToriyabeThe molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigenBioorg Med Chem1574347443200710.1016/j.bmc.2007.07.02817869524
21.	MO AndersonLY WuNM SantiagoSubstrate specificity of prostate-specific membrane antigenBioorg Med Chem1566786686200710.1016/j.bmc.2007.08.00617764959
22.	J MaungJP MallariTA GirtsmanProbing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidatesBioorg Med Chem1249694979200410.1016/j.bmc.2004.06.031
23.	DA WolfT HerzingerH HermekingD BlaschkeW HorzTranscriptional and posttranscriptional regulation of human androgen receptor expression by androgenMol Endocrinol792493619938413317
24.	Y NiuTM ChangS YehWL MaYZ WangC ChangDifferential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer failsOncogene2935933604201010.1038/onc.2010.12120440270
25.	JS RossCE SheehanHA FisherCorrelation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancerClin Cancer Res963576362200314695135
26.	S PernerMD HoferR KimProstate-specific membrane antigen expression as a predictor of prostate cancer progressionHum Pathol38696701200710.1016/j.humpath.2006.11.01217320151
27.	JM KokontisN HayS LiaoProgression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27^Kip1 in androgen-induced cell cycle arrestMol Endocrinol12941953199810.1210/mend.12.7.01369658399
28.	N IshikuraH KawataA NishimotoR NakamuraN IshiiY AokiEstablishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10Prostate70457466201019902465
29.	H SuzukiT UedaT IchikawaH ItoAndrogen receptor involvement in the progression of prostate cancerEndocr Relat Cancer10209216200310.1677/erc.0.010020912790784
30.	A ChlenskiK NakashiroKV KetelsGI KorovaitsevaR OyasuAndrogen receptor expression in androgen-independent prostate cancer cell linesProstate476675200110.1002/pros.104811304731
31.	P Mhawech-FaucegliaDJ SmiragliaW BsharaProstate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinomaCancer Epidemiol Biomarkers Prev17571577200810.1158/1055-9965.EPI-07-0511
32.	A GhoshX WangE KleinWD HestonNovel role of prostate-specific membrane antigen in suppressing prostate cancer invasivenessCancer Res65727731200515705868
33.	Y TangAW HamburgerL WangMA KhanA HussainAndrogen deprivation and stem cell markers in prostate cancersInt J Clin Exp Pathol3128138200920126580
34.	A GhoshWD HestonEffect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigenProstate57140151200310.1002/pros.1028912949938
35.	EH HolmesTG GreeneWT TinoAnalysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patientsProstateSuppl72529199610.1002/(SICI)1097-0045(1996)7+%3C25::AID-PROS3%3E3.0.CO;2-I
36.	C BarinkaP SachaJ SklenarIdentification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activityProtein Sci1316271635200410.1110/ps.0462210415152093
37.	R Luthi-CarterAK BarczakH SpenoJT CoyleHydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase IIBrain Res795341348199810.1016/S0006-8993(98)00244-39622670
38.	CW TiffanyRG LapidusA MerionDC CalvinBS SlusherCharacterization of the enzymatic activity of PSM: comparison with brain NAALADaseProstate392835199910.1002/(SICI)1097-0045(19990401)39:1%3C28::AID-PROS5%3E3.0.CO;2-A10221263
39.	R Luthi-CarterAK BarczakH SpenoJT CoyleMolecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase)J Pharmacol Exp Ther286102010251998